Therapeutic Options for Systemic Sclerosis: Current and Future Perspectives in Tackling Immune-Mediated Fibrosis

Area of Science:

• Rheumatology and Immunology
• Autoimmune Diseases
• Fibrotic Disorders

Background:

• Systemic sclerosis (SSc) is a severe autoimmune rheumatic disease.
• Characterized by excessive skin and visceral organ fibrosis.
• High morbidity and mortality with limited disease-modifying therapies.

Purpose of the Study:

• To examine the relationship between inflammation and fibrosis in SSc.
• To provide an overview of current and novel treatment efficacy for SSc-related fibrosis.
• To highlight potential therapeutic approaches based on clinical trials.

Main Methods:

• Narrative review of selected clinical trials.
• Discussion of innate and acquired immune inflammatory pathways in SSc.
• Exploration of first-line therapies, cell-specific treatments, and novel approaches.

Main Results:

• Inflammation, vasculopathy, and fibrosis are key pathological hallmarks of SSc.
• Review of current therapies and their efficacy in managing SSc fibrosis.
• Highlighting novel treatments, including tyrosine kinase inhibitors, for fibrosis reduction.

Conclusions:

• Understanding the interplay between inflammation and fibrosis is crucial for SSc management.
• Current therapies offer some benefit, but novel approaches are needed.
• Emerging treatments show promise in diminishing SSc-related fibrosis.